Home > Insider Trading > Jazz Pharmaceuticals Plc

Jazz Pharmaceuticals Plc (JAZZ)

Market is closed

Get Email Alerts

Profile
Hedge Fund Holdings
Insider Purchases
Insider Sales
Institutional Holdings
13 D/G Filings
News

Get Email Alerts

News

First
<< Previous
101 - 110
Next >>

Should You Avoid Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)?

In today’s marketplace, there are a multitude of gauges market participants can use to analyze their holdings. Two of the most innovative are hedge fund and insider trading movement.

Keep Reading →

August 27th, 2013 - News

What Hedge Funds Think About Medivation Inc (MDVN)

In today’s marketplace, there are a multitude of methods shareholders can use to monitor the equity markets. A couple of the most underrated are hedge fund and insider trading interest.

Keep Reading →

August 25th, 2013 - News

Regeneron Pharmaceuticals Inc (REGN), Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ): Have These 3 Biotechs Reached A Peak?

On Tuesday, several of biotechnology’s hottest names announced earnings. Despite strong results, the market appears to have grown accustomed to perfection.

Keep Reading →

August 12th, 2013 - News

Perrigo Company (PRGO), Elan Corporation, plc (ADR) (ELN): Will This Be the Next Irish Biotech Acquisition?

Perrigo Company (NYSE:PRGO)’s acquisition of Elan Corporation, plc (ADR) (NYSE:ELN) for $8.6 billion has been widely criticized by many as a way for Perrigo to avoid paying a high U.S.

Keep Reading →

August 8th, 2013 - News

Santarus, Inc. (SNTS), Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ): Three Earning Catalysts That Could Push This Biotech Even Higher

Santarus, Inc. (NASDAQ:SNTS) has traded higher by 250% over the last year, and much of those gains have been created after the company’s last two quarterly reports.

Keep Reading →

July 24th, 2013 - News

Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ), Onyx Pharmaceuticals, Inc. (ONXX), Seattle Genetics, Inc. (SGEN): Betting on Blockbusters

Global biotechnology industry revenue is expected to reach $262 billion this year showing growth of around 12.7% year over year.

Keep Reading →

July 22nd, 2013 - News

Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ), Novartis AG (ADR) (NVS): Don't Let Your Attention Defect

Ineffective drugs being sold for billions in global sales.

Keep Reading →

July 16th, 2013 - News

Questcor Pharmaceuticals Inc (QCOR): What Is the “True” Intention Behind This Market-Moving Drug Acquisition?

Questcor Pharmaceuticals Inc (NASDAQ:QCOR) saw a 15% gain on Tuesday. The large gains occurred after the company acquired rights to develop the autoimmune drug Synacthen in the U.S.

Keep Reading →

June 13th, 2013 - News